Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone levels in perilymph and CSF in vestibular schwannoma
NCT04658836Phase 1Completed
- Sponsor
- Medical University of Vienna
- Start
- Feb 2020
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of triamcinolone acetonide in vestibular schwannoma (VS), sponsored by Medical University of Vienna. Primary endpoint: Triamcinolone acetonide concentration in perilymph and CSF at 24 hours. Started Feb 2020; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
vestibular schwannoma (VS)
Beyond the preview
Go deeper on NCT04658836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04658836.